Hardman Johnston Global Advisors LLC Has $25.49 Million Holdings in Johnson & Johnson (JNJ)

Hardman Johnston Global Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 196,082 shares of the company’s stock after purchasing an additional 1,860 shares during the period. Johnson & Johnson makes up approximately 1.1% of Hardman Johnston Global Advisors LLC’s portfolio, making the stock its 25th biggest holding. Hardman Johnston Global Advisors LLC’s holdings in Johnson & Johnson were worth $25,493,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in JNJ. IFP Advisors Inc boosted its stake in shares of Johnson & Johnson by 1.2% in the 3rd quarter. IFP Advisors Inc now owns 180,440 shares of the company’s stock worth $23,459,000 after buying an additional 2,226 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Canada Pension Plan Investment Board now owns 4,732,866 shares of the company’s stock worth $615,320,000 after buying an additional 36,300 shares during the last quarter. Menora Mivtachim Holdings LTD. boosted its stake in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 172,460 shares of the company’s stock worth $22,422,000 after buying an additional 1,250 shares during the last quarter. Ramsay Stattman Vela & Price Inc. boosted its stake in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Ramsay Stattman Vela & Price Inc. now owns 66,676 shares of the company’s stock worth $8,668,000 after buying an additional 993 shares during the last quarter. Finally, Northwest Investment Counselors LLC boosted its stake in shares of Johnson & Johnson by 3.2% in the 3rd quarter. Northwest Investment Counselors LLC now owns 35,874 shares of the company’s stock worth $4,664,000 after buying an additional 1,119 shares during the last quarter. Institutional investors and hedge funds own 65.71% of the company’s stock.

Shares of Johnson & Johnson (JNJ) opened at $146.92 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $148.32. The stock has a market cap of $394,864.69, a price-to-earnings ratio of 25.51, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.29%. Johnson & Johnson’s payout ratio is 58.33%.

A number of brokerages have recently weighed in on JNJ. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a research note on Thursday, January 11th. Stifel Nicolaus upped their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research note on Wednesday, October 18th. Citigroup upped their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Finally, Argus upped their price objective on Johnson & Johnson from $145.00 to $165.00 and gave the company a “positive” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $145.94.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/19/hardman-johnston-global-advisors-llc-has-25-49-million-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply